Neratinib is alsobeing investigated in the adjuvant setting upon completion of trastuzumab-based therapy, as well as for neoadjuvanttreatment in locally advanced HER2/neu-positive breast cancer (NCT01008150). This evidence concerns the gene ERBB2 and breast cancer.